ATE185073T1 - Impfstoff zubereitungen - Google Patents

Impfstoff zubereitungen

Info

Publication number
ATE185073T1
ATE185073T1 AT94921761T AT94921761T ATE185073T1 AT E185073 T1 ATE185073 T1 AT E185073T1 AT 94921761 T AT94921761 T AT 94921761T AT 94921761 T AT94921761 T AT 94921761T AT E185073 T1 ATE185073 T1 AT E185073T1
Authority
AT
Austria
Prior art keywords
pct
date feb
sec
vaccine composition
hepatitis
Prior art date
Application number
AT94921761T
Other languages
English (en)
Inventor
Steven Neville Chatfield
Mark Roberts
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Application granted granted Critical
Publication of ATE185073T1 publication Critical patent/ATE185073T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT94921761T 1993-08-12 1994-07-29 Impfstoff zubereitungen ATE185073T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939316745A GB9316745D0 (en) 1993-08-12 1993-08-12 Vaccine compositions

Publications (1)

Publication Number Publication Date
ATE185073T1 true ATE185073T1 (de) 1999-10-15

Family

ID=10740372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94921761T ATE185073T1 (de) 1993-08-12 1994-07-29 Impfstoff zubereitungen

Country Status (12)

Country Link
US (2) US6129922A (de)
EP (1) EP0714307B1 (de)
JP (1) JP3883203B2 (de)
KR (1) KR100341958B1 (de)
AT (1) ATE185073T1 (de)
AU (1) AU674983B2 (de)
DE (1) DE69420970T2 (de)
DK (1) DK0714307T3 (de)
ES (1) ES2139083T3 (de)
GB (1) GB9316745D0 (de)
GR (1) GR3032134T3 (de)
WO (1) WO1995005194A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
CA2361377C (en) 1999-02-05 2009-02-03 Alk-Abello A/S Novel mucosal delivery system
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
AU2002366267B2 (en) * 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
KR100748842B1 (ko) 2004-09-09 2007-08-13 주식회사한국야쿠르트 에이형 간염바이러스에 대한 항체 제조방법 및 그 응용

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418626B1 (de) * 1989-09-08 1993-12-29 Takeda Chemical Industries, Ltd. Fusionsproteine und Herstellung davon
JPH03135923A (ja) * 1989-10-20 1991-06-10 Chemo Sero Therapeut Res Inst 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5549896A (en) * 1991-05-08 1996-08-27 Schweiz. Serum- & Impfinstitut Bern Hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
BR9506704A (pt) 1994-02-03 1997-09-09 Analogic Corp Aparelho e sistema de tomografia e processo de varredura de um objeto com um sistema de varredura topográfica
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same

Also Published As

Publication number Publication date
US6129922A (en) 2000-10-10
US20030007979A1 (en) 2003-01-09
DK0714307T3 (da) 2000-04-10
WO1995005194A1 (en) 1995-02-23
US6699480B2 (en) 2004-03-02
AU674983B2 (en) 1997-01-16
AU7235694A (en) 1995-03-14
EP0714307B1 (de) 1999-09-29
EP0714307A1 (de) 1996-06-05
ES2139083T3 (es) 2000-02-01
GB9316745D0 (en) 1993-09-29
GR3032134T3 (en) 2000-04-27
JP3883203B2 (ja) 2007-02-21
KR960703619A (ko) 1996-08-31
JPH09501437A (ja) 1997-02-10
DE69420970D1 (de) 1999-11-04
DE69420970T2 (de) 2000-03-30
KR100341958B1 (ko) 2003-03-15

Similar Documents

Publication Publication Date Title
FI944676A0 (fi) Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
DK1326636T3 (da) Vaccinesammensætning
DE69420970D1 (de) Impfstoff zubereitungen
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
KR920004422A (ko) Hiv의 주요 중화 결정인자
ATE154244T1 (de) Induzierung eines schutzes gegen virale infektionen
CA2168885A1 (en) Vaccine compositions
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
DE68922540T2 (de) Vorläufer des Hüllenglykoproteins des HIV-2 Retrovirus und verwandte Antigene.
KR20040000401A (ko) Ｈｉｖ 바이러스에 대한 천연 항체
ATE204761T1 (de) Pharmazeutische antigen-/antikörperpräparation

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee